{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:11:36Z","timestamp":1789009896153,"version":"build-2803163510"},"reference-count":81,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>After decades of virtually no progress, multiple myeloma survival has improved significantly in the past 10 years. Indeed, multiple myeloma has perhaps seen more remarkable progress in treatment and patient outcomes than any other cancer during the last decade. Recent data show that multiple myeloma is consistently preceded by a precursor state (monoclonal gammopathy of undetermined significance [MGUS]\/smoldering multiple myeloma [SMM]). This observation provides a framework for prospective studies focusing on transformation from precursor disease to multiple myeloma and for the development of treatment strategies targeting \u201cearly myeloma.\u201d This review discusses current biological insights in MGUS\/SMM, provides an update on clinical management, and discusses how the integration of novel biological markers, molecular imaging, and clinical monitoring of MGUS\/SMM could facilitate the development of early treatment strategies for high-risk SMM (early myeloma) patients in the future.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.478","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"478-487","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":67,"title":["Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies"],"prefix":"10.1182","volume":"2013","author":[{"given":"Ola","family":"Landgren","sequence":"first","affiliation":[{"name":"Multiple Myeloma Section, Metabolism Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2019111702550934500_B1","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies","volume":"117","author":"Korde","year":"2011","journal-title":"Blood"},{"issue":"23","key":"2019111702550934500_B2","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMc1211959","article-title":"MYD88 L265P somatic mutation in IgM MGUS","volume":"367","author":"Landgren","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111702550934500_B3","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"issue":"24","key":"2019111702550934500_B4","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111702550934500_B5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111702550934500_B6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2019111702550934500_B7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111702550934500_B8","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111702550934500_B9","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111702550934500_B10","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111702550934500_B11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2402797","article-title":"Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma","volume":"17","author":"Debes-Marun","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"2019111702550934500_B12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/sj.leu.2401041","article-title":"Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases","volume":"12","author":"Smadja","year":"1998","journal-title":"Leukemia"},{"issue":"3","key":"2019111702550934500_B13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/gcc.10275","article-title":"Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases","volume":"38","author":"Smadja","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2019111702550934500_B14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.leu.2403256","article-title":"Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonrandom acquisition of chromosomal changes","volume":"18","author":"Saez","year":"2004","journal-title":"Leukemia"},{"issue":"12","key":"2019111702550934500_B15","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"2019111702550934500_B16","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2009.011064","article-title":"Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"issue":"4","key":"2019111702550934500_B17","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"2019111702550934500_B18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2004-03-0833","article-title":"Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors","volume":"105","author":"Rasmussen","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111702550934500_B19","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2008.142","article-title":"Clinical and biological significance of RAS mutations in multiple myeloma","volume":"22","author":"Chng","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"2019111702550934500_B20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111702550934500_B21","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2019111702550934500_B22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3324\/haematol.2008.004440","article-title":"Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"issue":"5","key":"2019111702550934500_B23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"7339","key":"2019111702550934500_B24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"4","key":"2019111702550934500_B25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","article-title":"High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"issue":"12","key":"2019111702550934500_B26","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/leu.2012.128","article-title":"SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status","volume":"26","author":"Lopez-Corral","year":"2012","journal-title":"Leukemia"},{"issue":"7330","key":"2019111702550934500_B27","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature09650","article-title":"Genetic variegation of clonal architecture and propagating cells in leukaemia","volume":"469","author":"Anderson","year":"2011","journal-title":"Nature"},{"issue":"6","key":"2019111702550934500_B28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nrg1349","article-title":"Epigenomics: beyond CpG islands","volume":"5","author":"Fazzari","year":"2004","journal-title":"Nat Rev Genet"},{"issue":"7","key":"2019111702550934500_B29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc2876","article-title":"Covalent histone modifications\u2013miswritten, misinterpreted and mis-erased in human cancers","volume":"10","author":"Chi","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2019111702550934500_B30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrg2540","article-title":"Linking DNA methylation and histone modification: patterns and paradigms","volume":"10","author":"Cedar","year":"2009","journal-title":"Nat Rev Genet"},{"issue":"2","key":"2019111702550934500_B31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111702550934500_B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ydbio.2006.08.028","article-title":"microRNAs as oncogenes and tumor suppressors","volume":"302","author":"Zhang","year":"2007","journal-title":"Dev Biol"},{"issue":"35","key":"2019111702550934500_B33","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis","volume":"105","author":"Pichiorri","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2019111702550934500_B34","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J Clin Invest"},{"issue":"4","key":"2019111702550934500_B35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/erm.10.31","article-title":"Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis","volume":"10","author":"Balakumaran","year":"2010","journal-title":"Expert Rev Mol Diagn"},{"issue":"9","key":"2019111702550934500_B36","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2010-02-269126","article-title":"Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug","volume":"116","author":"Hu","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111702550934500_B37","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111702550934500_B38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111702550934500_B39","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2019111702550934500_B40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/ejh.12050","article-title":"Normalization of free light chain kappa\/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma","volume":"90","author":"Iwama","year":"2013","journal-title":"Eur J Haematol"},{"key":"2019111702550934500_B41","article-title":"Haematological cancer: treatment of smoldering multiple myeloma","author":"Rajkumar","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2019111702550934500_B42","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"issue":"9727","key":"2019111702550934500_B43","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"key":"2019111702550934500_B44","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study","author":"Cherry","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111702550934500_B45","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/leu.2012.189","article-title":"Suppression of uninvolved immunoglobulins defined by heavy\/light chain pair suppression is a risk factor for progression of MGUS","volume":"27","author":"Katzmann","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"2019111702550934500_B46","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2010-04-277566","article-title":"Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications","volume":"116","author":"Bianchi","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111702550934500_B47","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111702550934500_B48","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111702550934500_B49","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3109\/10428194.2012.740559","article-title":"Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging \u201cearly myeloma\u201d","volume":"54","author":"Hillengass","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2019111702550934500_B50","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","article-title":"Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111702550934500_B51","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0009-9260(67)80010-2","article-title":"The radiological demonstration of osseous metastases: experimental observations","volume":"18","author":"Edelstyn","year":"1967","journal-title":"Clin Radiol"},{"issue":"21","key":"2019111702550934500_B52","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2010.1713","article-title":"Multiple myeloma precursor disease","volume":"304","author":"Landgren","year":"2010","journal-title":"JAMA"},{"issue":"21","key":"2019111702550934500_B53","first-page":"2911","article-title":"Over 30% of smoldering myeloma patients have tumor cell bone marrow infiltration patterns similar to multiple myeloma: a large (n=544) clinical study using whole-body MRI [abstract]","volume":"120","author":"Hillengass","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9","key":"2019111702550934500_B54","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/archinte.1988.00380090051014","article-title":"Prognosis of asymptomatic multiple myeloma","volume":"148","author":"Alexanian","year":"1988","journal-title":"Arch Intern Med"},{"issue":"2","key":"2019111702550934500_B55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2013a randomized study. Myeloma Group of Western Sweden","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"issue":"21","key":"2019111702550934500_B56","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111702550934500_B57","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/10428190802005191","article-title":"Thalidomide and lenalidomide: Mechanism-based potential drug combinations","volume":"49","author":"Vallet","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019111702550934500_B58","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","article-title":"Thalidomide for previously untreated indolent or smoldering multiple myeloma","volume":"15","author":"Rajkumar","year":"2001","journal-title":"Leukemia"},{"issue":"8","key":"2019111702550934500_B59","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111702550934500_B60","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2009.01257.x","article-title":"Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma","volume":"82","author":"Stadtmauer","year":"2009","journal-title":"Eur J Haematol"},{"issue":"21","key":"2019111702550934500_B61","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111702550934500_B62","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111702550934500_B63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"2019111702550934500_B64","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2019111702550934500_B65","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","article-title":"Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111702550934500_B66","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"key":"2019111702550934500_B67","unstructured":"Lenalidomide or observation in treating patients with asymptomatic high-risk smoldering multiple myeloma\n          Accessed November 21, 2010\n          Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01169337?term=smoldering+myeloma&rank=6"},{"key":"2019111702550934500_B68","unstructured":"A phase II trial of IPH2101 (anti-KIR) in smoldering multiple myeloma (SMM)\n          Accessed November 21, 2010\n          Available from: http:\/\/clinicaltrials.gov\/ct2\/results?term=NCT01248455"},{"issue":"2","key":"2019111702550934500_B69","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4065\/84.2.114","article-title":"Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component","volume":"84","author":"Lust","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"18","key":"2019111702550934500_B70","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1158\/1078-0432.CCR-08-2217","article-title":"The potential role of curcumin in patients with monoclonal gammopathy of undefined significance\u2013its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker","volume":"15","author":"Golombick","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111702550934500_B71","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.4049\/jimmunol.171.7.3863","article-title":"Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells","volume":"171","author":"Bharti","year":"2003","journal-title":"J Immunol"},{"issue":"3","key":"2019111702550934500_B72","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood-2002-05-1320","article-title":"Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis","volume":"101","author":"Bharti","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2019111702550934500_B73","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.molonc.2008.09.006","article-title":"Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells","volume":"2","author":"Park","year":"2008","journal-title":"Mol Oncol"},{"issue":"7","key":"2019111702550934500_B74","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"2019111702550934500_B75","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3816\/CLM.2009.n.061","article-title":"Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important","volume":"9","author":"Berenson","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"2019111702550934500_B76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"2019111702550934500_B77","unstructured":"Kalaycio\n              ME\n            \n          \n          Celecoxib in preventing multiple myeloma in patients with monoclonal gammopathy or smoldering myeloma\n          2009\n          Accessed September 21, 2009\n          Bethesda\n          National Institutes of Health\n          Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00099047?term=Smoldering+OR+Indolent&cond=Multiple+Myeloma&rank=5"},{"key":"2019111702550934500_B78","unstructured":"Ballester\n              OF\n            \n          \n          Omega 3 supplementation for the prevention of disease progression in early stage chronic lymphocytic leukemia (ES-CLL), monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)\n          2009\n          Accessed September 21, 2009\n          Bethesda\n          National Institutes of Health\n          Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00899353?term=Smoldering+OR+Indolent&cond=Multiple+Myeloma&rank=7"},{"key":"2019111702550934500_B79","unstructured":"Zonder\n              JA\n            \n            \n              Shannon\n              K\n            \n          \n          Green tea extract in treating patients with monoclonal gammopathy of undetermined significance and\/or smoldering multiple myeloma\n          2009\n          Accessed September 21, 2009\n          Bethesda\n          National Institutes of Health\n          Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00942422?term=Smoldering+OR+Indolent&cond=Multiple+Myeloma&rank=6"},{"issue":"1","key":"2019111702550934500_B80","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"Witzig","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2019111702550934500_B81","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3816\/CLML.2010.n.053","article-title":"Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future","volume":"10","author":"Waxman","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/478\/1250988\/bep00113000478.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/478\/1250988\/bep00113000478.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T07:55:41Z","timestamp":1573977341000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/478\/20888\/Monoclonal-gammopathy-of-undetermined-significance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.478","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}